FENNEC PHARMACEUTICALS INC (FENC) Stock Price & Overview
NASDAQ:FENC • CA31447P1009
Current stock price
The current stock price of FENC is 6.73 USD. Today FENC is down by -0.88%. In the past month the price decreased by -8.06%. In the past year, price increased by 19.54%.
FENC Key Statistics
- Market Cap
- 232.05M
- P/E
- N/A
- Fwd P/E
- 15.65
- EPS (TTM)
- -0.27
- Dividend Yield
- N/A
FENC Stock Performance
FENC Stock Chart
FENC Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to FENC. When comparing the yearly performance of all stocks, FENC turns out to be only a medium performer in the overall market: it outperformed 44.55% of all stocks.
FENC Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to FENC. FENC has a great financial health rating, but its profitability evaluates not so good.
FENC Earnings
On March 24, 2026 FENC reported an EPS of -0.1 and a revenue of 13.78M. The company missed EPS expectations (-380.11% surprise) and missed revenue expectations (-3.48% surprise).
FENC Forecast & Estimates
13 analysts have analysed FENC and the average price target is 15.47 USD. This implies a price increase of 129.87% is expected in the next year compared to the current price of 6.73.
For the next year, analysts expect an EPS growth of 259.3% and a revenue growth 60.4% for FENC
FENC Groups
Sector & Classification
FENC Financial Highlights
Over the last trailing twelve months FENC reported a non-GAAP Earnings per Share(EPS) of -0.27. The EPS decreased by -486388759756013500% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -13.81% | ||
| ROE | -27.46% | ||
| Debt/Equity | 0 |
FENC Ownership
FENC Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.74 | 360.314B | ||
| AMGN | AMGEN INC | 15.33 | 188.978B | ||
| GILD | GILEAD SCIENCES INC | 15.37 | 168.645B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.55 | 111.71B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.99 | 79.228B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 45.55 | 41.489B | ||
| INSM | INSMED INC | N/A | 30.828B | ||
| NTRA | NATERA INC | N/A | 29.443B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 28.978B | ||
| BIIB | BIOGEN INC | 11.37 | 26.907B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.62 | 25.134B | ||
| MRNA | MODERNA INC | N/A | 21.65B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.477B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About FENC
Company Profile
Fennec Pharmaceuticals, Inc. is a specialty pharmaceutical company. The company is headquartered in Research Triangle Park, North Carolina. The company went IPO on 2001-06-05. The company sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is an approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. The company is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase III clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. The company has established Fennec HEARS, a single source program designed to connect PEDMARK patients.
Company Info
IPO: 2001-06-05
FENNEC PHARMACEUTICALS INC
PO Box 13628, 68 Tw Alexander Dr
RESEARCH TRIANGLE PARK NORTH CAROLINA 27709 US
CEO: Rostislav Raykov
Employees: 35
Phone: 19196364530
FENNEC PHARMACEUTICALS INC / FENC FAQ
What does FENC do?
Fennec Pharmaceuticals, Inc. is a specialty pharmaceutical company. The company is headquartered in Research Triangle Park, North Carolina. The company went IPO on 2001-06-05. The company sells its product through a field force, including Regional Pediatric Oncology Specialists and medical science liaisons who are helping to educate the medical communities and patients about cisplatin induced ototoxicity and its programs supporting patient access to PEDMARK. PEDMARK is an approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. The company is a formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is a therapeutic agent with a dosing paradigm, across two open-label, randomized Phase III clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6. The company has established Fennec HEARS, a single source program designed to connect PEDMARK patients.
Can you provide the latest stock price for FENNEC PHARMACEUTICALS INC?
The current stock price of FENC is 6.73 USD. The price decreased by -0.88% in the last trading session.
What is the dividend status of FENNEC PHARMACEUTICALS INC?
FENC does not pay a dividend.
What is the ChartMill rating of FENNEC PHARMACEUTICALS INC stock?
FENC has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Which stock exchange lists FENC stock?
FENC stock is listed on the Nasdaq exchange.
What sector and industry does FENNEC PHARMACEUTICALS INC belong to?
FENNEC PHARMACEUTICALS INC (FENC) operates in the Health Care sector and the Biotechnology industry.
Can you provide the growth outlook for FENNEC PHARMACEUTICALS INC?
The Revenue of FENNEC PHARMACEUTICALS INC (FENC) is expected to grow by 60.4% in the next year. Check the estimates tab for more information on the EPS, Sales, EBIT and EBITDA future analyst estimates.